Adjusted tight control blood glucose management in diabetic patients undergoing on pump coronary artery bypass graft. A randomized clinical trial

Abstract

Background: Many of the patients who are undergoing Coronary Artery Bypass Graft have diabetes mellitus or metabolic syndrome and are at risk for hyperglycemia events. Objective: The present study aimed to compare conventional glucose control with adjusted tight control in patients undergoing on-pump CABG. Methods: This double –blind randomized clinical trial study was conducted in Shiraz, Iran, from September 2017–March 2018. Two consecutive groups of 75 patients undergoing elective on- pump coronary artery bypass graft surgery. Intervention: The patients were divided into adjusted tight control of the blood glucose between 100 and 120 mg/dl and conventional method that the blood glucose maintained ≤200 mg/dl. Primary outcomes were: mortality, sternal wound infection, cardiac arrhythmia, cerebrovascular attack, and acute renal failure. Secondary outcomes included: duration of mechanical ventilation and length of ICU staying. The same main outcomes were evaluated after one month. Statistical analysis: The data were analyzed using SPSS version 20(SPSS, Chicago, IL). Group comparisons were performed using t-tests and Chi-square tests. Repeated measurement test was used for comparing blood glucose in two groups. Mann Whitney U test was compared duration of the mechanical ventilation and length of ICU staying. Statistical significance was defined as a p value <0.05. Results: There were no significant differences between main and secondary outcomes. About late outcomes, sternal wound infection was in the control group (7 patients) more than intervention (1 patient) (P < 0.05). No differences between other complications in both groups were observed. The occurrence of hypoglycemia was low in both groups. Hypokalemia was significantly higher in the intervention than in control (P < 0.001). Conclusions: The findings showed using adjusted tight glycemic control to a level that is nearby to normal values during cardiac surgery may reduce episodes of hypoglycemia and thus reduces its side effects. As well as reduce hyperglycemic complications such as sternal wound infection. Trial registration number: IRCT2013041713052N1). 2013-07-09.